RIGL Rigel Pharmaceuticals
- 1.110
- +0.010+0.91%
Rigel Pharmaceuticals News
12 Health Care Stocks Moving In Monday's After-Market Session
GainersNuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. The company's market cap stands at $3.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 7.42% to
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26%
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders that were waiting for something to happen have been dealt a blow with a 26% share price drop in the last month. The recent drop has obliterate
Express News | Rigel Pharmaceuticals: on April 11, Entered Amendment to Credit & Security Deal of Sept 27, 2019 to Extend Maturity for Term Loans to Sept 1, 2027
Rigel Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the...
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients With Mutant IDH1 AML in Leukemia & Lymphoma
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the Phase 2 ...
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year
Rigel Pharmaceuticals Is Maintained at Buy by Citigroup
Rigel Pharmaceuticals Is Maintained at Buy by Citigroup
Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $4
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $3 to $4.
New Corporate Activity and Growth Risk for Rigel Pharmaceuticals – What's the Latest?
Rigel Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
Rigel Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
Rigel Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Rigel Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Express News | B. Riley Securities Maintains Neutral on Rigel Pharmaceuticals, Maintains $1.25 Price Target
Earnings Call Summary | Rigel Pharmaceuticals(RIGL.US) Q4 2023 Earnings Conference
The following is a summary of the Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Call Transcript:Financial Performance:Rigel recorded 2023 sales of $104 million for TAVALISSE and REZLIDHIA, a gro
Rigel Pharmaceuticals GAAP EPS of $0.00 Beats by $0.02, Revenue of $35.8M Beats by $2.39M
Rigel Pharmaceuticals Inc. Q4 Earnings Summary
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q4 Revenue $35.8M, Vs. Street Est of $33.4M
04:02 PM EST, 03/05/2024 (MT Newswires) -- Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q4 Revenue $35.8M, vs. Street Est of $33.4M
Press Release: Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., March 5, 2024 -- Fourth quarter 2023 Total Revenue of $35.
Rigel Pharmaceuticals 4Q EPS 0c >RIGL
Rigel Pharmaceuticals 4Q EPS 0c >RIGL
Earnings Scheduled For March 5, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. • Target (NYSE:TGT) is estimated to report quarterly earnings
Analysis
Price Target
No Data
